Recruiting

Chronic Airway Disease and Multimorbidity Cohort

ClinicalTrials.gov IDNCT06798077

PhaseNot Applicable

Enrollment2000

SponsorChina-Japan Friendship Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis

About this study

Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization. Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.

Primary outcomes

Length of hospital stay (From the date of admission until discharge or death, assessed over an estimated period of 3 to 30 days.)

Eligibility information

Inclusion Criteria: * Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age; * The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis". Exclusion Criteria: * Patients were unable to undergo spirometry during the stabilization period; * Expected survival is less than 1 month; * Refusal to sign an informed consent form; * Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion; * Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.

Study locations

National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, Beijing Municipality 100029 China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280 China
Henan Provincial People's Hospital, Zhengzhou, Henan 450003 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022 China
The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011 China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001 China
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710114 China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai Municipality 200025 China
West China Hospital of Sichuan University, Chengdu, Sichuan 610041 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.